Xiaojiang Jiang

Third Military Medical University, Ch’ung-ch’ing-shih, Chongqing Shi, China

Are you Xiaojiang Jiang?

Claim your profile

Publications (4)3.79 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the synergistic effect of dexmedetomidine and cognitive behavioral therapy (CBT) on chronic insomnia. Forty-six chronic insomnia patients were selected and randomly assigned to the CBT group (CBT-I) or the CBT combined with dexmedetomidine (CBT-I + DEX) group. The sleep indexes and polysomnographic parameters were assessed before treatment, 4 weeks after treatment, and 8 weeks after treatment. The daily sleep conditions were recorded during the entire treatment course. Eight patients in the CBT-I group quit treatment, with a success rate of 65.2 %, and two patients in the CBT-I + DEX group quit treatment, with a success rate of 91.3 %, revealing a significant difference between the two groups (P < 0.05). At 4 and 8 weeks after treatment, the soma-arousal level was significantly decreased in the CBT-I + DEX group compared with the CBT-I group (P < 0.01), but no significant difference in the cognitive arousal. Polysomnographic monitoring results show that the sleep time at non-REM stage 3 (N3) and the total sleep time in the CBT-I + DEX group was longer than the CBT-I group after 4 weeks of treatment (P < 0.05). The number of awakenings, sleep latency, REM sleep latency and sleep efficiency were significantly improved in both groups at the end of treatment (P < 0.05), but the total sleep time was not obviously increased in both groups. Dexmedetomidine hydrochloride-induced sleep effectively reduced the patients’ arousal level, prolonged deep sleep, reduced the degree of daytime sleepiness, and improved the success rate of CBT.
    No preview · Article · Dec 2015 · Sleep and Biological Rhythms
  • Jia Chen · Xiaomin Liang · Binghu Li · Xiaojiang Jiang · Zhiqiang Xu
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Epidemiological studies have evaluated the associations between brain-derived neurotrophic factor (BDNF) 196A/G gene polymorphism and Alzheimer's disease (AD) risk. However, the results remain inconclusive. Sexually dimorphic effect of the polymorphism of BDNF 196A/G in AD patients had been proposed previously, specifically in female group. With more cases reported, therefore, we perform a meta-analysis of published case-control studies to better understand these results. We systematically searched online databases of Embase, PubMed and Web of Science, as well as hand searching of the references of identified articles and meeting abstracts. Review Manager (Version 5.2.4) and Stata software (Version 12.0) were used for statistical analyses. The pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. A total of 23 publications including 25 studies were identified and entered the analysis. No significant association was observed in overall population, as well as subgroups stratified by ethnicity (Caucasian and Asian). However, when stratified by gender, significant association was observed just in female subgroup (A allele vs. G allele: OR = 1.15, 95% CI = 1.06-1.25; A/A vs. G/G: OR = 1.29, 95% CI = 1.06-1.57; A/A + A/G vs. G/G: OR = 1.30, 95% CI = 1.11-1.53). This meta-analysis confirmed the gender-related association between BDNF 196A/G polymorphism and AD risk, which may indicate a certain effect of female hormone on progression of the disease. Larger sample size and more studies with homogeneous AD patients and well-matched controls are needed in future.
    No preview · Article · Nov 2013 · The International journal of neuroscience
  • Source
    Qiansheng Li · Wenqian Huo · Keqin Zhang · Gang Wu · Fengshuo Jin · Xi Lin · Xiaojiang Jiang · Dong Gao

    Preview · Chapter · Aug 2011
  • Zhiqiang Xu · Xiaojiang Jiang · Wei Li · Dong Gao · Xunjun Li · Juan Liu
    [Show abstract] [Hide abstract]
    ABSTRACT: Insomnia, defined as difficulty in falling asleep and/or staying asleep, short sleep duration, or poor quality sleep, is a common sleep disorder affecting 30-40% of adult population. We have conducted a randomized, double-blind, placebo-controlled study to test if anesthesia is therapeutically beneficial in patients with refractory chronic primary insomnia. We have assessed the efficacy and safety of propofol-induced sleep in these patients. This study comprised of 103 patients with refractory chronic primary insomnia (including 59 non-pregnant, non-lactating women; 28-60 years) and the participants were randomized to receive either physiological saline (placebo) (n = 39) or 3.0 g/l propofol (n = 64) in a 2-h continuous intravenous infusion for five consecutive nights. The Leeds Sleep Evaluation Questionnaire was used for the subjective assessment of sleep, and polysomnography was used for the objective measurement of sleep architecture and patterns. The assessments were done prior to and at the end of the 5-day treatment and 6 months after treatment period. The adverse effects of the treatment were also recorded. A 2-h continuous intravenous infusion of 3.0 g/l propofol for five consecutive nights improved the subjective and objective assessments of sleep in 64 patients with refractory chronic primary insomnia. This improvement occurred immediately after the therapy and persisted for 6 months. No serious adverse events were noticed during the period of drug administration or 6 months after the treatment. Propofol therapy is an efficacious and safe choice for restoring normal sleep in patients with refractory chronic primary insomnia.
    No preview · Article · Nov 2010 · Cell biochemistry and biophysics

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.